25 Jul 2012

Bordeaux accredited with BRIO!

The BRIO project (Bordeaux Oncology Integrated Research) led by the Institut Bergonié, partnering teams from the Bordeaux University Hospital, the Bordeaux Segalen University and the Bordeaux University PRES (Center for Research and Higher Studies), is one of the 6 projects selected by INCa (National Cancer Institute).

INCa has just accredited 6 six new sites for integrated research on Cancer (SIRIC), bringing the total to eight in France. This accreditation enables INCa to consolidate one of the key measures of the 2009-2013 Cancer Plan aiming to strengthen the resources for multidisciplinary research.  SIRIC is funded by the Ministry of Health, INCa and Inserm on behalf of Aviesan.

SIRIC programs aim to bring together and organize, in an integrated manner and on the same site, preclinical and clinical research, and research in human and social sciences, epidemiology and public health. They must thus perform, to maximum optimization, research programs combining multidisciplinary components, from preclinical research to the transfer to patients, in the form of diagnostic tests, drugs, social or public health action (prevention and screening).

Six programs are included in BRIO, SIRIC Bordeaux. Four programs focus on specific tumors: breast cancers (NéoBreastnet: neoadjuvant and post-neoadjuvant breast cancer therapy), sarcoma (an integrated program geared towards personalized treatment of sarcomas), myeloid tumors (leukemic hematopoiesis and therapeutic targets) and liver tumors (hepatocellular carcinoma and liver metastasis). Two programs are transversely oriented: Geriatric Oncology (from suboptimal to optimal treatment of cancers in the elderly) and Innovative Molecular Targets and cancer treatment. Moreover, we have set up an additional program for the transmission of the results of our research to patients and to the public (How can we improve patient access to information and promote the transfer of research results and interdisciplinary practices?).

Professor Josy Reiffers, Director of the Institut Bergonié

“… Recognition of this SIRIC is a major step enabling us to effectively formalize all relevant forces towards a common goal, intensify our exchanges between teams from different disciplines and maximize our effectiveness in relation to patients …”

Professors Pierre Soubeyran (Director of BRIO) and Francois-Xavier Mahon (Deputy Director)

“… Research in oncology conducted by university hospitals should be dedicated to the transfer of results towards patients. To be competitive and innovative, it must be set up with the competent structures, hospitals licensed to treat cancer patients, Universities and Research Units. Moreover, this research must be linked to clinical routine to ensure that the results are effectively transferred to patients. Finally, research must make our strategies converge toward our ultimate goal, improving the care of patients and their prognosis. These principles are the basis of the general strategy of SIRIC Bordeaux, BRIO, and its recognition by the INCA, the INSERM and the DGOS puts us in the best position to carry out our various assignments to the benefit of patients.”

French-style “Comprehensive Cancer Centers”, or Centers for comprehensive care

There are now eight French sites, five in the provinces including Bordeaux and three in the Paris area, with responsibility for major research programs which are exemplary in coherence, discipline integration and competitiveness.

The SIRIC will also be responsible for locally and nationally spreading the knowledge gained from the results of their work. The SIRIC and INCa share objectives of coordination, complementarity and synergy to increase the French position in innovative approaches to personalized medicine for cancer, and the societal dimension of its support.

Just like the “Comprehensive Cancer Centers” of the United States or the British “cancer research”, the French SIRIC aim to give a strong boost for a high-level of multidisciplinary research and ultimately, to increase the performance of French cancer research in all its aspects: biological, clinical, human and social, epidemiological and relating to public health.

Finally the SIRIC fall within a more comprehensive structure for cancer research, developed by INCa around specific infrastructures (molecular genetics platforms, tumor banks, clinical-biological databases, Centers for early-phase clinical trials…), with which they must be articulated.

PRESS CONTACT: GERALD CARMONA (Head of Communication, Institut Bergonié)

Tel. +33 (0)6 14 96 57 94